Deucravacitinib Shows Efficacy Signal in Cutaneous Lupus Erythematosus
Deucravacitinib (Sotyktu, Bristol-Myers Squibb) may help improve cutaneous manifestations in patients with systemic lupus erythematosus, according to a late-breaking study presented at MauiDerm 2024. Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with moderate to severe plaque psoriasis. In the 48-week, double-blind, phase […]
FDA Green Lights Leo’s Adbry for Kids With AD
The U.S. Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the first and only FDA-approved biologic that specifically […]
Wound Healing Breakthrough: A New Sustainable Hydrogel Based on Seaweed Exhibits Lower Skin Adhesion, Swelling
A novel, low-cost hydrogel using a component found in seaweed may aid wound healing, according to new research in the International Journal of Biological Macromolecules. The hydrogel was made using alginate, calcium carbonate, and carbonated water. Alginate is a biocompatible substance that can be extracted from beach-cast seaweed that does not adhere strongly to cells or skin tissues. […]
Meet the 2023 NEA Grant Winners
The National Eczema Association (NEA) announced the recipients for its 2023 research grants. This is the 20th anniversary of NEA’s grant program. So far, the NEA has invested nearly $4 million since its first grant was awarded in 2004. The 2023 research grantees include: The Champion Research Grant encourages researchers to continue research on emerging or ongoing challenges in eczema […]